NasdaqCM:CBLI

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Cleveland BioLabs, Inc., a biopharmaceutical company, develops novel approaches to activate the immune system and address various medical needs in the United States and Russia. More Details


Snowflake Analysis

Flawless balance sheet with weak fundamentals.

Share Price & News

How has Cleveland BioLabs's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: CBLI is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 11% a week.

Volatility Over Time: CBLI's weekly volatility has decreased from 43% to 11% over the past year.


Market Performance


7 Day Return

11.2%

CBLI

0.7%

US Biotechs

1.4%

US Market


1 Year Return

271.4%

CBLI

40.9%

US Biotechs

22.6%

US Market

Return vs Industry: CBLI exceeded the US Biotechs industry which returned 41.5% over the past year.

Return vs Market: CBLI exceeded the US Market which returned 22.8% over the past year.


Shareholder returns

CBLIIndustryMarket
7 Day11.2%0.7%1.4%
30 Day29.7%5.2%4.9%
90 Day56.2%23.7%14.6%
1 Year271.4%271.4%43.2%40.9%25.4%22.6%
3 Year8.2%8.2%27.1%20.5%46.8%37.0%
5 Year10.0%10.0%58.4%46.0%132.0%106.1%

Long-Term Price Volatility Vs. Market

How volatile is Cleveland BioLabs's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Cleveland BioLabs undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether Cleveland BioLabs is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Cleveland BioLabs has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

Future Growth

How is Cleveland BioLabs forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

20.9%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Cleveland BioLabs has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

  • Examine Cleveland BioLabs's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  • Explore growth companies in the Pharmaceuticals & Biotech industry.

Past Performance

How has Cleveland BioLabs performed over the past 5 years?

19.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: CBLI is currently unprofitable.

Growing Profit Margin: CBLI is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: CBLI is unprofitable, but has reduced losses over the past 5 years at a rate of 19.6% per year.

Accelerating Growth: Unable to compare CBLI's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CBLI is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-10.3%).


Return on Equity

High ROE: CBLI has a negative Return on Equity (-88.69%), as it is currently unprofitable.


Next Steps

Financial Health

How is Cleveland BioLabs's financial position?


Financial Position Analysis

Short Term Liabilities: CBLI's short term assets ($3.2M) exceed its short term liabilities ($483.9K).

Long Term Liabilities: CBLI has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: CBLI is debt free.

Reducing Debt: CBLI has no debt compared to 5 years ago when its debt to equity ratio was 14.3%.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: CBLI has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: CBLI has sufficient cash runway for 1.2 years if free cash flow continues to grow at historical rates of 30.8% each year.


Next Steps

Dividend

What is Cleveland BioLabs's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate CBLI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate CBLI's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CBLI's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CBLI's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CBLI's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

6.0yrs

Average management tenure


CEO

Christopher Zosh (45 yo)

1.08yrs

Tenure

US$103,494

Compensation

Mr. Christopher Zosh has been the Interim Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer of Cleveland BioLabs, Inc. since December 13, 2019 and has been its Vice ...


CEO Compensation Analysis

Compensation vs Market: Christopher's total compensation ($USD103.49K) is below average for companies of similar size in the US market ($USD533.25K).

Compensation vs Earnings: Christopher's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Christopher Zosh
VP of Finance1.08yrsUS$103.49kno data
Andrei Gudkov
Chief Scientific Officer17.58yrsUS$66.14k0.57%
$ 308.0k
Langdon Miller
Chief Medical Officer6yrsUS$73.73k0%
$ 0

6.0yrs

Average Tenure

64yo

Average Age

Experienced Management: CBLI's management team is seasoned and experienced (6 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Randy Saluck
Independent Director4.5yrsUS$35.00k0.0010%
$ 568.5
Anna Evdokimova
Independent Director5.5yrsno datano data
Daniil Talyanskiy
Independent Director4.5yrsno datano data
Lea Verny
Independent Chair of the Board4.5yrsUS$35.00kno data
Alexander Andryuschechkin
Independent Director4.5yrsno datano data
Ivan Fedyunin
Independent Director2.42yrsno datano data

4.5yrs

Average Tenure

40yo

Average Age

Experienced Board: CBLI's board of directors are considered experienced (4.5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 18%.


Top Shareholders

Company Information

Cleveland BioLabs, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Cleveland BioLabs, Inc.
  • Ticker: CBLI
  • Exchange: NasdaqCM
  • Founded: 2003
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$54.146m
  • Shares outstanding: 13.34m
  • Website: https://www.cbiolabs.com

Number of Employees


Location

  • Cleveland BioLabs, Inc.
  • 73 High Street
  • Buffalo
  • New York
  • 14203
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CBLINasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDJul 2006
7CB1DB (Deutsche Boerse AG)YesCommon StockDEEURJul 2006

Biography

Cleveland BioLabs, Inc., a biopharmaceutical company, develops novel approaches to activate the immune system and address various medical needs in the United States and Russia. Its proprietary platform of ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/01/21 23:57
End of Day Share Price2021/01/21 00:00
Earnings2020/09/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.